bioRxivGenomicsPreprint
Evaluation of persistence and fate of ex vivo edited-HSC modified with donor template and Its role in correcting Sickle Cell Disease
Sowmya PattabhiiD, Samantha N. Lotti, Mason P. Berger, Swati SinghiD, David J. RawlingsiD
Abstract
Sickle cell disease (SCD) is caused by a single nucleotide transversion in exon 1 of the HBB gene that changes the hydrophobicity of adult globin ({beta}A), leading to substantial morbidity and reduced lifespan. Ex vivo autologous gene editing utilizing co-delivery of a designer nuclease along with a DNA donor template allows for precise homology-directed repair (HDR). These gene corrected cells when engrafted into the bone marrow (BM) can prove to be therapeutic and serves as an alternative to HLA-matched BM transplantation. In the current study, we extensively explored the role of single stranded oligonucleotide (ssODN) and recombinant adeno-associated 6 (rAAV6) donor template delivery to introduce a codon-optimized change (E6optE) or a sickle mutation (E6V) change following Crispr/Cas9-mediated cleavage of HBB in healthy human mobilized peripheral blood stem cells (mPBSCs). We achieved efficient HDR in vitro in edited cells and observed robust human CD45+ engraftment in the BM of NBSGW mice at 16-17 weeks. Notably, recipients of ssODN-modified HSC exhibited a significantly higher proportion of HDR-modified cells within individual BM, CD34+ and CD235+ compartments of both E6optE and E6V cohorts. We further assessed key functional outcomes including RNA transcripts analysis and globin sub-type expression. Our combined findings demonstrate the capacity to achieve clinically relevant HDR in vitro and in vivo using both donor template delivery method. The use of ssODN donor template-delivery is consistently associated with higher levels of gene correction in vivo as demonstrated by sustained engraftment of HDR-modified HSC and erythroid progeny. Finally, the HDR-based globin protein expression was significantly higher in the E6V ssODN-modified animals compared to the rAAV6-modified animals confirming that the ssODN donor template delivery outperforms rAAV6-donor template delivery.
- organism: human
- assay: DNA methylation
- assay: whole-genome sequencing
- research focus: gene regulatory network inference
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cas9-AAV6 Gene Correction of Beta-Globin in Autologous HSCs Improves Sickle Cell Disease Erythropoiesis in Mice
Adam C. Wilkinson, Daniel P. Dever, … Matthew Hebden Porteus·Nature CommunicationsPeer-reviewed·Jan 29, 2021
- Efficient Correction of the Sickle Mutation in Human Hematopoietic Stem Cells Using a Cas9 Ribonucleoprotein Complex
Mark A. DeWitt, Wendy Magis, … Jacob E. Corn·bioRxiv·Jan 15, 2016
- High-level correction of the sickle mutation amplified in vivo during erythroid differentiation
Wendy Magis, Mark A. DeWitt, … David I. K. Martin·bioRxiv·Jan 8, 2019
- Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease
Varun Katta, Kiera O’Keefe, … Shengdar Q. Tsai·Molecular TherapyPeer-reviewed·Jul 30, 2024
- Development of Gene Editing Strategies for Human β-Globin (HBB) Gene Mutations
Batuhan Mert Kalkan, Ezgi Yağmur Kala, … Fatih Kocabaş·GenePeer-reviewed·Jan 24, 2020
- Safety and efficacy study of CRISPR/Cas9 treatment of sickle cell disease in clinically relevant conditions highlights disease-specific response
G. Frati, M. Brusson, … A. Miccio·bioRxiv·Jan 14, 2024